Navigation Links
VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Date:11/26/2007

Xyfid in the first half of 2008. In addition, VioQuest and the U.S. Army are planning to submit a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) in 2008 for Lenocta for the treatment of leishmaniasis.

Further information about VioQuest can be found at http://www.vioquestpharm.com.

This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These forward-looking statements concern the timing, progress and results of the clinical development, regulatory processes, and potential clinical trial initiations of Lenocta. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. These statements are subject to various risks and uncertainties and include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM), will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Laboratories, Inc. (OTCBB: UGNE), a leader in ... therapeutics, today announced the Company,s Vice President of ... presenting at IBC,s 4th Annual AsiaTIDES Oligonucleotide and ... Hotel in Tokyo, Japan. The TIDES ...
... DIEGO, Feb. 27, 2012 Optimer Pharmaceuticals, Inc. (NASDAQ: ... and fiscal year 2011 financial results and provide a ... the NASDAQ Global Market closes on March 7th.  The ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). ...
Cached Medicine Technology:Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and PeptideĀ® Conference 2Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and PeptideĀ® Conference 3Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results 2
(Date:7/10/2014)... (HealthDay News) -- Nature, not nurture, may play the ... a new study finds. "As is the case ... [thinking] abilities in chimpanzees," William Hopkins of the Yerkes ... news release from the journal Current Biology . ... evolution of intelligence in humans, Hopkins, team said. ...
(Date:7/10/2014)... (HealthDay News) -- Teens who are sensitive to light ... develop emotional symptoms such as anxiety and depression, a ... that may exacerbate issues teens experience after concussion may ... making decisions about when to return to play and ... study authors Lisa Koehl and Dong Han, of the ...
(Date:7/10/2014)... By Dennis Thompson ... -- Forget about the Twitter wars that break out regularly ... can be bad for your own relationship, a new study ... friction within a couple, even if the couple is in ... of 581 Twitter users. In turn, that friction can ...
(Date:7/10/2014)... (Boston) Emergency Medical Service (EMS) responders felt better ... receiving focused tactical training according to a new study ... This is the first study to specifically examine the ... scene where a shooter has not yet been neutralized ... , Incidents such as the Columbine High School shooting, ...
(Date:7/10/2014)... Reducing the amount of alcoholic beverages consumed, even ... a reduced risk of coronary heart disease, lower ... to a new multi-center study published in ... School of Medicine at the University of Pennsylvania. ... which suggest that consuming light-to-moderate amounts of alcohol ...
Breaking Medicine News(10 mins):Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:New study shows drinking alcohol provides no heart health benefit 2
... N.C., June 2 Typical ninth graders are worried about fitting ... from middle school, or keeping up with the latest popular trends--they ... next or other mobility issues. But Luis Magana is not a ... Although Magana was diagnosed with brain cancer almost four years ago, ...
... regain lost trust , TUESDAY, June 2 (HealthDay News) -- ... for not informing the public about its inner workings, announced ... how to be more transparent. , "This is an ... FDA and its processes more transparent to the public," FDA ...
... ... and health and wellness spa treatments that complement conventional medicine through a unique weekend series ... ... Resort & Spa has partnered with Mayo Clinic for the first time ...
... Merchants Inc (NMI), a global leader in payment gateway technologies, ... $50,000 to Schaumburg,s Children,s Home & Aid Family Center. , ... in Schaumburg," said NMI,s CEO Jim McKenzie. "Children,s Home & ... deserves a chance can benefit," McKenzie added. , ...
... Pa., June 2 Royal ... today introduced the Trilogy100 portable at-home life-support ... kg) device marks a milestone in home ventilation from ... bi-level positive airway pressure for noninvasive ventilation nearly 20 ...
... may be more effective than gastric bypass, researchers say ... called duodenal switch surgery may be more effective than ... such as high cholesterol, diabetes and high blood pressure, ... patients who were more than 200 pounds heavier than ...
Cached Medicine News:Health News:The SCOOTER Store Donates Scooter to North Carolina Student With Brain Cancer 2Health News:The SCOOTER Store Donates Scooter to North Carolina Student With Brain Cancer 3Health News:FDA to Study Ways to Be More Open With Public 2Health News:FDA to Study Ways to Be More Open With Public 3Health News:The Westin Kierland Resort And Mayo Clinic Present "Well Beyond" Weekend 2Health News:The Westin Kierland Resort And Mayo Clinic Present "Well Beyond" Weekend 3Health News:The Westin Kierland Resort And Mayo Clinic Present "Well Beyond" Weekend 4Health News:Network Merchants, Inc (NMI) Founders Donate $50,000 to Schaumburg's Children's Home & Aid 2Health News:Photos: Philips Expands Home Healthcare Commitment With Portable Life-Support Ventilator; Offers Ease of Use, Portability and Versatility for Patient 2Health News:Photos: Philips Expands Home Healthcare Commitment With Portable Life-Support Ventilator; Offers Ease of Use, Portability and Versatility for Patient 3Health News:Weight-Loss Surgery Options Compared in Super-Obese 2